Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Immutep (IMM) says its final trial results have given it confidence that its drug can deliver clinical improvement for cancer patients
  • 227 patients with metastatic breast cancer took part in a randomised, placebo-controlled study, evaluating Immutep’s lead product candidate eftilagimod alpha (efti) in combination with paclitaxel chemotherapy
  • The trial showed patients in the efti group had a median overall survival of 20.4 months, compared to 17.5 months for patients in the comparator group
  • The research data will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021
  • Immutep shares fell 16.4 per cent, trading at 58.5 cents at 1:04 pm AEDT

Immutep (IMM) said its final trial results have given it confidence its drug can deliver clinical improvement for cancer patients.  

The company received final results from its Phase IIb Active Immunotherapy Paclitaxel (AIPAC) trial.

Under the trial, 227 patients with HER2-negative/HR positive metastatic breast cancer took part in a randomised, placebo-controlled study. The trial evaluated Immutep’s lead product candidate eftilagimod alpha (efti) in combination with paclitaxel chemotherapy, compared to a combination of placebo and paclitaxel chemotherapy.

The trial showed patients in the efti group had a median overall survival of 20.4 months, compared to 17.5 months for patients in the comparator group.

The combination of efti and paclitaxel chemotherapy was also declared safe and well tolerated.

Immutep CEO Marc Voigt said the results have given the company additional confidence that efti can ultimately deliver a meaningful clinical improvement for diverse sets of cancer patients.

“The results from our AIPAC trial are especially pleasing because metastatic breast cancer patients in the chemotherapy setting are a difficult to treat and large patient population where immunotherapies often fail to provide an additional benefit,” Mr Voigt said.

The data is being presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, running from November 10 to 14.

Immutep is now preparing a Phase III investigation of efti in combination with paclitaxel in metastatic breast cancer.

Immutep shares fell 16.4 per cent, trading at 58.5 cents at 1:04 pm AEDT.

IMM by the numbers
More From The Market Herald
X2M Connect (ASX:X2M) - Chief Operating Officer, Keith Jelley

" X2M Connect (ASX:X2M) signs two service contracts in South Korea

X2M Connect (ASX:X2M) has secured two new Software-as-a-Service (SaaS) and maintenance contracts with Gochang County and…
North Stawell Minerals (ASX:NSM) - Non Executive Chairman, Jerry Ellis

" North Stawell Minerals (ASX:NSM) extends Gellatlys gold trend to 3.5km

North Stawell Minerals' (ASX:NSM) recent aircore drilling program has extended the Gellatlys gold trend to 3.5…

" Rafaella Resources’ (ASX:RFR) Santa Comba shows improved recoveries

Rafaella Resources (ASX:RFR) has revealed positive metallurgical testwork results from the Spanish Santa Comba project which…
Raiz Invest (ASX:RZI) - CEO, George Lucas

" Raiz Invest (ASX:RZI) FUM surpasses $1 billion

Raiz Invest (ASX:RZI) has reported its funds under management (FUM) has passed the $1 billion benchmark…